ATXS
Price
$12.44
Change
-$0.11 (-0.88%)
Updated
Nov 13 closing price
Capitalization
710.14M
111 days until earnings call
Intraday BUY SELL Signals
BOLT
Price
$4.70
Change
+$0.01 (+0.21%)
Updated
Nov 13 closing price
Capitalization
9.09M
Intraday BUY SELL Signals
Interact to see
Advertisement

ATXS vs BOLT

Header iconATXS vs BOLT Comparison
Open Charts ATXS vs BOLTBanner chart's image
Astria Therapeutics
Price$12.44
Change-$0.11 (-0.88%)
Volume$577.82K
Capitalization710.14M
Bolt Biotherapeutics
Price$4.70
Change+$0.01 (+0.21%)
Volume$60.57K
Capitalization9.09M
ATXS vs BOLT Comparison Chart in %
ATXS
Daily Signal:
Gain/Loss:
BOLT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATXS vs. BOLT commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and BOLT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ATXS: $12.44 vs. BOLT: $4.70)
Brand notoriety: ATXS and BOLT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 27% vs. BOLT: 204%
Market capitalization -- ATXS: $710.14M vs. BOLT: $9.09M
ATXS [@Biotechnology] is valued at $710.14M. BOLT’s [@Biotechnology] market capitalization is $9.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileBOLT’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • BOLT’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATXS and BOLT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 2 TA indicator(s) are bullish while BOLT’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 2 bullish, 6 bearish.
  • BOLT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BOLT is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а +0.08% price change this week, while BOLT (@Biotechnology) price change was -1.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

ATXS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($710M) has a higher market cap than BOLT($9.09M). ATXS YTD gains are higher at: 39.150 vs. BOLT (-56.083). BOLT has higher annual earnings (EBITDA): -51.83M vs. ATXS (-131.42M). ATXS has more cash in the bank: 259M vs. BOLT (34.8M). ATXS has less debt than BOLT: ATXS (4.77M) vs BOLT (24.2M). BOLT has higher revenues than ATXS: BOLT (4.17M) vs ATXS (0).
ATXSBOLTATXS / BOLT
Capitalization710M9.09M7,809%
EBITDA-131.42M-51.83M254%
Gain YTD39.150-56.083-70%
P/E RatioN/AN/A-
Revenue04.17M-
Total Cash259M34.8M744%
Total Debt4.77M24.2M20%
FUNDAMENTALS RATINGS
ATXS: Fundamental Ratings
ATXS
OUTLOOK RATING
1..100
88
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATXSBOLT
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 19 days ago
73%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signal:
Gain/Loss:
BOLT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BSM13.66-0.10
-0.73%
Black Stone Minerals LP
BZH21.40-0.38
-1.74%
Beazer Homes USA
ADXN8.60-0.21
-2.38%
Addex Therapeutics Ltd
TLK20.57-0.64
-3.02%
PT Telekomunikasi Indonesia
SLSN1.64-0.30
-15.46%
Solesence Inc

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with SYRE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-0.88%
SYRE - ATXS
50%
Loosely correlated
-3.41%
XENE - ATXS
49%
Loosely correlated
+0.91%
RGNX - ATXS
47%
Loosely correlated
+0.34%
ORKA - ATXS
46%
Loosely correlated
-6.78%
DNLI - ATXS
46%
Loosely correlated
-2.11%
More

BOLT and

Correlation & Price change

A.I.dvisor indicates that over the last year, BOLT has been loosely correlated with MGNX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BOLT jumps, then MGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLT
1D Price
Change %
BOLT100%
+0.21%
MGNX - BOLT
34%
Loosely correlated
+8.84%
ATXS - BOLT
34%
Loosely correlated
-0.88%
RNAC - BOLT
34%
Loosely correlated
-4.62%
XENE - BOLT
33%
Loosely correlated
+0.91%
ELVN - BOLT
32%
Poorly correlated
-0.15%
More